Krakow, Poland, April 06, 2018 / B3C newswire / -- Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the most recent data from its oncology programs at the upcoming AACR Annual Meeting 2018, which will take place on April 14-18 2018, in Chicago, IL, USA.
Data presented at the conference will include recent results from Selvita’s CDK8 inhibitor program, SEL120, developed in cooperation with The Leukemia and Lymphoma Society in the area of acute myeloid leukemia, as well as two discovery phase projects targeting cancer immunometabolism: SHMT2 small molecule inhibitors and dual A2A/A2B adenosine receptor antagonists.
“We are very glad to be able to present new results from our early discovery projects. We see our immunometabolism programs as important and very promising assets in our pipeline. At the same time we are presenting the most recent results from our most advanced fully-owned oncology program – SEL120 – which is on track to start Phase I in 1Q2019” - said Krzysztof Brzozka, Chief Scientific Officer at Selvita.
The results from Selvita research and development programs will be presented in the following poster sessions:
- The poster presentation recapping the most recent results of SEL120 project development, entitled “CDK8 inhibitor SEL120-34A targets CD34 positive AML cells by regulation of various transcriptional programs involved in maintenance of leukemia stem cells”, Abstract no. 5829, will take place on Wednesday, April 18, between 8:00 AM – 12:00 PM, during the session “Experimental and Molecular Therapeutics”; “Combination Chemotherapy 2”, in the McCormick Place South, Exhibit Hall A, Poster Section 37, poster board #25.
- The poster presentation entitled: “Discovery of novel SHMT small molecule inhibitors for cancer treatment”, Abstract no. 3516, will take place during the session “Molecular and Cellular Biology / Genetics”; “Therapeutic Approaches”, on Tuesday, April 17, between 8:00AM – 12:00 PM, in the McCormick Place South, Exhibit Hall A, Poster Section 22, poster board #13.
- The poster presentation entitled: “Characterization of novel dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy”, Abstract no: 3770, will take place during the session “Immunology”; “Immunomodulatory Agents and Interventions 1”, on Tuesday, April 17, between 8:00AM – 12:00 PM, in the McCormick Place South, Exhibit Hall A, Poster Section 32, poster board #20.
Selvita Oncology Pipeline
In its internal research and development efforts, Selvita focuses on different dimensions of oncology. The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, which was exclusively licensed to Menarini Group in March 2017. The second most advanced program is SEL120, a first-in-class small molecule inhibitor of CDK8 with potential use in hematological malignancies, colorectal cancer and breast cancer. In August 2017, Selvita signed a partnering agreement with The Leukemia and Lymphoma Society for preclinical and Phase I clinical development of SEL120 in area of AML, within the Therapy Acceleration Program. Several Selvita’s research programs have been partnered with Merck/EMD Serono, H3 Biomedicine/Eisai and Nodthera. Selvita Early Discovery Programs are focused on a number of novel oncology targets in the area of kinase inhibitors, cancer metabolism & immunometabolism and immunooncology.
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).
+48 784 069 418